Full text is available at the source.
Utilization of Anti-obesity Medications After Bariatric Surgery: Analysis of a Large National Database
Use of Weight-Loss Drugs After Weight-Reduction Surgery: Study of a Large National Database
AI simplified
Abstract
Among 59,160 adults who underwent bariatric surgery, topiramate was the most commonly prescribed anti-obesity medication, with a prevalence of 8%.
- The prevalence of anti-obesity medication (AOM) use after bariatric surgery was highest for topiramate, followed by liraglutide at 2.9%, phentermine/topiramate at 1.03%, naltrexone/bupropion at 0.95%, semaglutide at 0.52%, and orlistat at 0.17%.
- Age-specific trends in AOM utilization were noted, with topiramate being most used among individuals aged 35-39, and liraglutide and orlistat most used in those aged 65-69.
- Higher AOM usage was observed among African American individuals across all medications studied.
- Comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus were significantly associated with increased AOM use.
AI simplified